Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma - Phase II trials of the Minnie Pearl Cancer Research Network
Jd. Hainsworth et al., Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma - Phase II trials of the Minnie Pearl Cancer Research Network, CANCER, 92(9), 2001, pp. 2391-2398
BACKGROUND. The current study was conducted to evaluate the feasibility, to
xicity, and efficacy of weekly docetaxel when paired with either gemcitabin
e or vinorelbine as the second-line treatment of patients with advanced non
small cell lung carcinoma.
METHODS. Patients with progressive nonsmall cell lung carcinoma after one p
revious chemotherapeutic regimen, an Eastern Cooperative Oncology Group per
formance status of 0-2, and measurable lesions were eligible for treatment
in these Phase II trials. Patients who had not received gemcitabine previou
sly were treated with docetaxel, 30 mg/m(2), and gemcitabine, 800 mg/m(2),
both of which were administered intravenously (i.v.) on Days 1, 8, and 15 o
f a 28-day cycle. if the patients had received gemcitabine as part of first
-line therapy, they were treated with docetaxel, 30 mg/m(2), and vinorelbin
e, 20 mg/m(2) i.v., on Days 1, 8, and 15 of a 28-day cycle. Patients were r
eevaluated after two courses of treatment, and responding patients continue
d treatment for six courses or until disease progression.
RESULTS. Forty patients were treated with a combination of docetaxel and ge
mcitabine, and 23 patients received docetaxel and vinorelbine. The docetaxe
l/gemcitabine combination was reasonably well tolerated, with moderate myel
osuppression and a few nonhematologic toxicities reported. The objective re
sponse rate was 10%, with a 1-year survival rate of 20%. The docetaxel/vino
relbine combination was found to be poorly tolerated, with Grade 3/4 leukop
enia reported in 71% of patients and neutropenic fever reported in 70% of p
atients despite frequent dose reductions and omission of the Day 15 doses.
Enrollment onto this regimen was stopped prematurely due to toxicity, and a
fter no major responses were observed in the first 20 evaluable patients.
CONCLUSIONS. The combination of weekly docetaxel/gemcitabine appears to be
feasible and relatively well tolerated as second-line treatment in patients
with advanced nonsmall cell lung carcinoma, whereas a weekly combination o
f docetaxel and vinorelbine did not appear to be tolerable at the doses and
schedule used in the current study. Neither regimen showed a level of acti
vity that suggested any advantage compared with the results obtained with s
ingle-agent docetaxel in this setting. (C) 2001 American Cancer Society.